Aims: Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with T2DM who live in hot climates.
are limited in these areas. 3 Therefore, patients must find ways to adapt their disease management in warmer weather conditions to avoid potentially serious complications, adverse events (AEs) and hospitalisations. 1 Approximately, 90% of people with diabetes have type 2 diabetes mellitus (T2DM), which is characterised by hyperglycaemia, insulin resistance, and impaired beta-cell function. 3 Because uncontrolled hyperglycaemia can lead to microvascular and macrovascular complications of T2DM, 4 many organisations recommend that patients with T2DM implement lifestyle changes and/or begin treatment with antihyperglycaemic agents (AHAs) in order to lower their blood glucose levels. 5 Metformin is the first-line AHA recommended when diet and exercise are insufficient to control hyperglycaemia; selection of additional AHAs is usually at the discretion of the clinician, whose recommendations may vary depending on individual patient characteristics and the risk/benefit profiles of available agents. 5 However, there remains a large contingency of patients with T2DM who are unable to control their disease with currently available treatment options. 6 Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, is an oral AHA that is approved in many countries for the treatment of adults with T2DM. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Canagliflozin lowers plasma glucose by increasing urinary glucose excretion, which also results in a mild osmotic diuresis and a net caloric loss. [22] [23] [24] [25] Across Phase 3 studies, canagliflozin has been associated with reductions in HbA1c, body weight and blood pressure (BP), and was generally well tolerated, with an increased incidence of AEs related to the mechanism of SGLT2 inhibition (e.g. genital mycotic infections, osmotic diuresis-related AEs) and low incidence of volume depletion-related AEs. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Canagliflozin has also demonstrated a low risk of hypoglycaemia when not used in conjunction with AHAs associated with hypoglycaemia (e.g. insulin, sulphonylureas).
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The mild osmotic diuresis associated with the SGLT2 inhibitor mechanism of action may increase the risk of volume depletion in some patients. This manuscript reports the efficacy and safety of canagliflozin in two populations of patients with T2DM who live in countries with hot climates, including a pooled data set representative of the general T2DM population and a long-term data set from an active-controlled study that enrolled a large number of patients from countries with hot climates.
| MATERIALS AND METHODS

| Patients and study design
Post hoc efficacy and safety analyses were conducted in two populations of patients with T2DM who were enrolled in study centres that are located in countries with hot climates (i.e. defined as being located predominantly between the Tropics of Cancer and Capricorn, Details of individual study designs, including randomisation and blinding, have been reported for the placebo-controlled studies [7] [8] [9] [10] and the active-controlled study. 14 Briefly, the placebo-controlled studies consisted of a 26-week core treatment period, followed by a 26-week extension treatment period; data from the core treatment periods were included in this analysis. Patients who were eligible for the placebo-controlled studies generally included adults with T2DM who were 18-80 years of age and were inadequately controlled (HbA1c ≥7.0% and ≤10.5%) on protocol-specified background therapy. The active-controlled study consisted of a 52-week core treatment period, followed by a 52-week extension treatment period. Patients who were eligible for the active-controlled study included adults with T2DM who were 18-80 years of age and were inadequately controlled
What's known
• Patients with type 2 diabetes mellitus (T2DM) have increased risk of dehydration and hypoglycaemia in hot weather.
• Canagliflozin, a sodium glucose co-transporter 2 inhibitor, lowers plasma glucose in patients with T2DM by increasing urinary glucose excretion, which results in a mild osmotic diuresis and net caloric loss.
• Canagliflozin was generally well tolerated across Phase 3 studies, with low rates of volume depletions-related adverse events.
What's new
• Efficacy and safety of canagliflozin were evaluated in patients with T2DM living in hot climates using pooled data from placebo-controlled studies and data from an active-controlled study.
• Canagliflozin 100 and 300 mg improved glycaemic control and lowered body weight and blood pressure in patients living in hot climates.
• Canagliflozin was generally well tolerated in patients living in hot climates, with low incidences of volume depletion-related AEs.
(HbA1c ≥7.0% and ≤9.5%) on metformin ≥2000 mg (or ≥1500 mg if higher doses were not tolerated). Glimepiride was uptitrated from 1 to 6 or 8 mg (based on maximum approved dose in the country of the investigational site; mean dose, 6.8 mg) if patients met protocolspecified glycaemic criteria. In all studies, glycaemic rescue therapy complementary to the protocol-specified background AHA was initiated using protocol-specified glycaemic criteria. 
| Statistical analyses
These post hoc analyses were conducted using the modified intent- 
| RESULTS
| Patients
In the pooled, placebo-controlled studies, the hot climate subset pooled, placebo-controlled studies (Table 2 ) and the active-controlled study (Table 3) respectively, in the other climate subset (Fig. 1A) . Relative to placebo, dose-dependent reductions in FPG were seen with canagliflozin 100
and 300 mg in both subsets (Fig. 1B) .
Active-controlled Study
Relative to glimepiride, canagliflozin 100 and 300 mg provided LS in the other climate subset at week 104 ( Fig. 2A) . Dose-dependent reductions in FPG were seen with canagliflozin 100 and 300 mg compared with glimepiride in both subsets (Fig. 2B ).
| Body weight and BP
Pooled, placebo-controlled studies
In the hot climate subset, canagliflozin 100 and 300 mg provided per cent reductions in body weight compared with placebo that were consistent with those seen in patients living in other climates over 26 weeks (Fig. 3) . Because of the lower baseline body weight in the hot climate subset, absolute changes in body weight were smaller in the hot climate subset than in the other climate subset. Compared with placebo, canagliflozin 100 and 300 mg provided reductions in systolic BP (Fig. 4A ) and diastolic BP in the hot climate and other climate subsets at week 26 (Fig. 4B ).
Active-controlled study
Canagliflozin 100 and 300 mg were associated with reductions in body weight, whereas an increase in body weight was seen with glimepiride in the hot climate and other climate subsets at week 104 (Fig. 5) . Numerically larger reductions in systolic BP were seen with canagliflozin 100 and 300 mg compared with glimepiride in patients living in hot climates at week 104; systolic BP reductions were also seen with both canagliflozin doses in the other climate subset compared with a small increase with glimepiride (Fig. 6A) . Canagliflozin 100 and 300 mg provided numerical reductions in diastolic BP compared with glimepiride in the hot climate and other climate subsets at week 104 (Fig. 6B ).
| Safety
Pooled, placebo-controlled studies
Canagliflozin 100 and 300 mg were generally well tolerated in the hot climate subset, with a safety profile similar to that seen in patients living in other climates (Table 4 ). The overall incidence of AEs was similar across groups, with low rates of AEs leading to discontinuation and serious AEs in both subsets.
The incidence of osmotic diuresis-related AEs was higher with canagliflozin 100 and 300 mg compared with placebo in both the hot climate subset (5.0%, 2.2%, and 0.6%, respectively) and the other climate subset (7.4%, 6.9%, and 0.8%, respectively); pollakiuria was the most commonly reported osmotic diuresis-related AE with canagliflozin in both subsets. The incidence of volume depletion-related AEs with canagliflozin 100 and 300 mg and placebo was 0.9%, 0.9% and 0%, respectively, in the hot climate subset, and 1.3%, 1.5% and 1.4%, respectively, in the other climate subset. Specific AEs related to volume depletion that were reported in the canagliflozin-treated patients in the hot climate subset included postural dizziness (n=2), orthostatic hypotension (n=1) and syncope (n=1). There were no AEs of dehydration reported in the hot climate subset, and one patient in the canagliflozin 300 mg group from the other climate subset reported dehydration. Of The incidence of male genital mycotic infections was higher with canagliflozin 100 and 300 mg compared with placebo in the hot climate subset (3.7%, 6.4% and 0%, respectively) and the other climate subset (4.3%, 3.1% and 0.8%, respectively). At baseline, 83% of men in the hot climate subset and 56% of men in the other climate subset were uncircumcised, and circumcision status was balanced across treatment groups; 94% of men in the hot climate subset and 95% of men in the other climate subset had no history of balanitis. The incidence of female genital mycotic infections was also higher with canagliflozin 100 and 300 mg compared with placebo in the hot climate subset (6.4%, 6.8% and 1.1%, respectively) and the other climate subset (12.3%, 13.8% and 4.1%, respectively). The incidence of UTIs with canagliflozin 100 and 300 mg and placebo was 9.5%, 7.1% and 7.4%, respectively, in the hot climate subset, and 4.6%, 3.3% and 2.9%, respectively, in the other climate subset.
Among patients who were not on background sulphonylurea, documented hypoglycaemia rates with canagliflozin 100 and 300 mg and placebo were 6.5%, 4.0% and 1.5%, respectively, in the hot climate in the other climate subset. The incidence of severe hypoglycaemia episodes was low across groups and ≤1.0% with canagliflozin in both subsets.
Active-controlled study
Canagliflozin 100 and 300 mg were generally well tolerated compared with glimepiride in the hot climate subset, with a safety profile similar to that seen in patients from other climates ( Table 5 ). The overall incidence of AEs was similar across groups in the hot climate subset;
there was no notable trend in the incidences of AEs leading to discontinuation or serious AEs. 
| DISCUSSION
Canagliflozin 100 and 300 mg improved glycaemic control and lowered body weight and BP compared with placebo and glimepiride in patients with T2DM who live in hot climates, consistent with findings from patients who live in other climates. Canagliflozin 100 and F I G U R E 6 Change from baseline in (A) systolic BP and (B) diastolic BP in the hot climate and other climate subsets the activecontrolled study at week 104. LS, least squares; SE, standard error; BP, blood pressure; CI, confidence interval; GLIM, glimepiride; CANA, canagliflozin
Per cent change from baseline in body weight in the hot climate and other climate subsets of the active-controlled study at week 104. LS, least squares; SE, standard error; CI, confidence interval; GLIM, glimepiride; CANA, canagliflozin 300 mg were also generally well tolerated in the hot climate subsets of the pooled, placebo-controlled studies and the active-controlled study, with a safety and tolerability profile that was generally consistent with that seen in patients living in other climates.
Because the mechanism of canagliflozin is associated with a potential for increased risk of AEs related to osmotic diuresis and volume depletion, 26 these AEs may be of concern for patients with T2DM in hot climates who are at increased risk of dehydration. b Possibly, probably or very likely related to study drug, as assessed by investigators.
c PBO, n=71; CANA 100 mg, n=81; CANA 300 mg, n=78 in the hot climate subset. PBO, n=263; CANA 100 mg, n=327; CANA 300 mg, n=326 in the other climate subset.
d Includes balanitis, balanitis candida and balanoposthitis in the hot climate subset; and balanitis, balanitis candida, balanoposthitis and genital infection fungal in the other climate subset.
e PBO, n=92; CANA 100 mg, n=141; CANA 300 mg, n=148 in the hot climate subset. PBO, n=220; CANA 100 mg, n=284; CANA 300 mg, n=282 in the other climate subset. The incidence of osmotic diuresis-related AEs was higher with both canagliflozin doses vs placebo in both subsets of the pooled, placebo-controlled studies; in the active-controlled study, the incidence of osmotic diuresis-related AEs was similar across groups in the hot climate subset. The incidence of osmotic diuresis-related
AEs associated with urination (e.g. pollakiuria, polyuria, nocturia, urine output increased) was lower in patients from hot climates vs those who were from other climates. There was no imbalance in the incidence of volume depletion-related AEs in either subset; specifically, no AEs of dehydration were reported with canagliflozin among patients in both hot climate subsets. Of note, the observed incidence of volume depletion-related AEs was lower than the proportion of patients who were at higher risk of these AEs.
Consistent with previous results across studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and in those living in other climates, canagliflozin was associated with higher incidences of male and female genital mycotic infections compared with placebo or glimepiride in the hot climate subset of each population; the overall incidence of genital mycotic infections was lower across groups in the hot climate subset compared with the other climate subset. There was no clear trend in UTI incidence with canagliflozin vs either placebo or glimepiride; however, UTI incidence was generally higher across groups in the hot climate subsets compared with the other climate subsets. Previous studies have suggested that there is seasonality for the incidence of UTIs, with more UTIs reported during warmer months. 27 It has been postulated that this trend may be related, in part, to dehydration, which can decrease the frequency of urination; swimming in natural bodies of water; warm weather creating a suitable environment for bacterial transfer to the urethra; or poor sanitation and contaminated drinking water. 27, 28 Patients with T2DM who live in warm climates have a high risk of hypoglycaemia, primarily because of the increased likelihood of dehydration. 29 The incidence of documented hypoglycaemia was higher who fast during the holy month of Ramadan, many of whom also live in warmer climates. 30 Changes in eating and drinking habits during this time may increase the risk of hypoglycaemia and dehydration; therefore, medications that can be used to control T2DM with a low risk of these AEs would be beneficial. 30 To date, there have been limited studies of SGLT2 inhibitors in patients with T2DM during Ramadan
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; therefore, safety findings from the current analysis in patients from hot climates may help to inform clinician decisions related to T2DM management during Ramadan.
The efficacy of canagliflozin 100 and 300 mg in the hot climate subsets of each study was consistent with trends observed in the broader study populations, including improvements in glycaemic efficacy and reductions in body weight and systolic BP. 
